In Chile, acute ischemic stroke represents one of the leading public health burdens, with cerebrovascular disease ranking as the top cause of mortality in recent years reportedly 52 deaths per 100,000 persons in 2010, and significant years of life lost particularly among adults over 60. The Ministry of Health’s national stroke plan (“Plan Nacional de Accidente Cerebrovascular”) alongside clinical guidelines, established since 2013, has introduced the concept of “Código ACV” to accelerate diagnosis and enable timely thrombolytic intervention within the critical 4.5‑hour window. This coordinated emergency response system has been a fundamental driver in increasing accessibility to acute ischemic stroke drugs in Chile
TABLE - Chile Acute Ischemic Stroke Drugs Market Size & Forecast By Drug Class 2021-2033
Drug Class | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Thrombolytics | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Anticoagulant | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Antiplatelet | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Neuroprotective Agent | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis